UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 51

Sortiert nach

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

The journal of clinical endocrinology and metabolism, 2024-01, Vol.109 (2), p.361-369

2024

Volltextzugriff (PDF)

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

The journal of clinical endocrinology and metabolism, 2024-05

2024

Volltextzugriff (PDF)

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Advances in therapy, 2023-08, Vol.40 (8), p.3434-3445

2023

Volltextzugriff (PDF)

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group

Pharmaceutical research, 2023-07, Vol.40 (7), p.1601-1631

2023

Volltextzugriff (PDF)

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Effects of Tirzepatide on Eating Behavior: A Phase 1 Study in People Living with Obesity

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.39-40

2023

Volltextzugriff (PDF)

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

AN ELISA FOR QUANTIFICATION OF T84.66, A MONOCLONAL ANTI-CEA ANTIBODY, IN MOUSE PLASMA

Journal of immunoassay & immunochemistry, 2010-01, Vol.31 (1), p.1-9

2010

Volltextzugriff (PDF)

The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying

Diabetes, obesity & metabolism, 2023-09, Vol.25 (9), p.2784-2788

2023

Volltextzugriff (PDF)

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

Clinical pharmacology and therapeutics, 2024-07

2024

Volltextzugriff (PDF)

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

British journal of clinical pharmacology, 2016-05, Vol.81 (5), p.958-970

2016

Volltextzugriff (PDF)

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

Blood, 2014-12, Vol.124 (21), p.3228-3228

2014

Volltextzugriff (PDF)

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

Investigational new drugs, 2012-12, Vol.30 (6), p.2344-2351

2012

Volltextzugriff (PDF)

Meta-analysis on the relationship between everolimus exposure and safety and efficacy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3099-3099

2012

Volltextzugriff (PDF)

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

International journal of gynecological cancer, 2014-03, Vol.24 (3), p.528-533

2014

Volltextzugriff (PDF)

26 – 50 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(21)
Pharmacokinetics
(19)
Diabetes
(17)
Glucagon
(15)
Antidiabetics
(13)
Male
(12)
Pharmacology & Pharmacy
(12)
Diabetes Mellitus
(11)
Adult
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(10)
Clinical Trials
(9)
Middle Aged
(9)
Weight Control
(9)
Animals
(8)
Body Weight
(8)
Dosage
(8)
Drug Dosages
(8)
Endocrinology & Metabolism
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Effects of Tirzepatide on Eating Behavior: A Phase 1 Study in People Living with Obesity

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity

AN ELISA FOR QUANTIFICATION OF T84.66, A MONOCLONAL ANTI-CEA ANTIBODY, IN MOUSE PLASMA

The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

Meta-analysis on the relationship between everolimus exposure and safety and efficacy

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Suchergebnisse filtern